Pin Wang, PhD

Professor

Websites

Is this your profile? Click to edit

Phone +1 213 740 0780

Email [email protected]

CTSI Profile

Overview

The Wang laboratory focuses on an emerging field of “immunobioengineering” with the aim of employing engineering tools and principles to quantitatively understand the immune system in health and disease and to develop novel molecular and cellular immunotherapies by precisely modulating disease-specific immune responses. The ongoing research research projects include: 1) exploring various strategies to engineer virus-derived vector systems for dendritic cell-targeted vaccine delivery and oncolytic virus-based immunotherapy; 2) designing and optimizing cellular immunotherapy that is based on molecular engineering of chimeric antigen receptors (CARs); 3) exploring immune cells as drug carriers for targeted delivery of immunomodulatory drugs to enhance cancer immunotherapy; 4) exploring systems biology tools for modeling and understanding details of signaling pathways mediated by designer molecules such as chimeric antigen receptors to activate T cells; 5) developing engineering methods to improve adeno-associated virus (AAV)-based gene delivery. In this research laboratory, bioengineers collaborate with chemists, immunologists, computer scientists, and system biologists to directly address problems in translational immunology and develop and optimize innovative approaches to improve lives of patients suffering from cancer and infectious diseases.

Research Funding

In situ Redirection of T cell Specificity and Imaging of Targeted CAR Expression.
NIH · R01EB017206 · Sep 1, 2013 – Aug 31, 2020 · Role: Co-Principal Investigator
SUPR Peptides to Inhibit Undruggable Cancer Target (PQ18)
NIH · R01CA170820 · Sep 17, 2012 – Jun 30, 2017 · Role: Co-Principal Investigator
Targeting lentiviruses to infect chosen cells
NIH · R01AI068978 · Feb 1, 2006 – Jan 31, 2012 · Role: Principal Investigator

Research Keywords

Cancer Immunotherapy
Immunoengineering
T Cell Engineering
Chimeric Antigen Receptor
Cancer Vaccine
Gene Therapy
Immuno-Oncology

Media

AIDS: USC Says Prof Pin Wang Has Invented 'A Virus That Hunts Down HIV-Infected Cells'

Publications

Targeted gene delivery to CD117-expressing cells in vivo with lentiviral vectors co-displaying stem cell factor and a fusogenic molecule. Biotechnol Bioeng. 2009 Sep 01; 104(1):206-15.. View in PubMed
Pulsatile shear stress increased mitochondrial membrane potential: implication of Mn-SOD. Biochem Biophys Res Commun. 2009 Oct 16; 388(2):406-12.. View in PubMed
Engineering fusogenic molecules to achieve targeted transduction of enveloped lentiviral vectors. J Biol Eng. 2009 Jun 02; 3:8.. View in PubMed
Cell type-specific targeting with surface-engineered lentiviral vectors co-displaying OKT3 antibody and fusogenic molecule. Pharm Res. 2009 Jun; 26(6):1432-45.. View in PubMed
In vitro differentiation of adult bone marrow progenitors into antigen-specific CD4 helper T cells using engineered stromal cells expressing a notch ligand and a major histocompatibility complex class II protein. Stem Cells Dev. 2009 Mar; 18(2):235-45.. View in PubMed
Engineering human hematopoietic stem/progenitor cells to produce a broadly neutralizing anti-HIV antibody after in vitro maturation to human B lymphocytes. Blood. 2009 Feb 12; 113(7):1422-31.. View in PubMed
Gamma-retroviral vectors enveloped with an antibody and an engineered fusogenic protein achieved antigen-specific targeting. Biotechnol Bioeng. 2008 Oct 01; 101(2):357-68.. View in PubMed
Targeting lentiviral vectors to antigen-specific immunoglobulins. Hum Gene Ther. 2008 Sep; 19(9):861-72.. View in PubMed
Site-specific labeling of enveloped viruses with quantum dots for single virus tracking. ACS Nano. 2008 Aug; 2(8):1553-62.. View in PubMed
CD4+CD25- T cells transduced to express MHC class I-restricted epitope-specific TCR synthesize Th1 cytokines and exhibit MHC class I-restricted cytolytic effector function in a human melanoma model. J Immunol. 2008 Jul 15; 181(2):1063-70.. View in PubMed